LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 18

Search options

  1. Article ; Online: Microenvironment-dependent growth of Sezary cells in humanized IL-15 mice.

    Gao, Jie / Ren, Shumei / Choonoo, Gabrielle / Chen, Guoying / Frleta, Davor / Zhong, Jun / Gupta, Namita / Sharma, Prachi / Oyejide, Adelekan / Atwal, Gurinder S / Macdonald, Lynn / Murphy, Andrew / Kuhnert, Frank

    Disease models & mechanisms

    2023  Volume 16, Issue 10

    Abstract: Sezary syndrome (SS) is a rare, aggressive leukemic variant of cutaneous T-cell lymphoma (CTCL) that lacks adequate therapeutic options and representative small-animal models. Here, we demonstrate that IL-15 is a critical CTCL growth factor. Importantly, ...

    Abstract Sezary syndrome (SS) is a rare, aggressive leukemic variant of cutaneous T-cell lymphoma (CTCL) that lacks adequate therapeutic options and representative small-animal models. Here, we demonstrate that IL-15 is a critical CTCL growth factor. Importantly, an immunodeficient knock-in mouse model genetically engineered to express human IL-15 uniquely supported the growth of SS patient samples relative to conventional immunodeficient mouse strains. SS patient-derived xenograft (PDX) models recapacitated key pathological features of the human disease, including skin infiltration and spread of leukemic cells to the periphery, and maintained the dependence on human IL-15 upon serial in vivo passaging. Detailed molecular characterization of the engrafted cells by single-cell transcriptomic analysis revealed congruent neoplastic gene expression signatures but distinct clonal engraftment patterns. Overall, we document an important dependence of Sezary cell survival and proliferation on IL-15 signaling and the utility of immunodeficient humanized IL-15 mice as hosts for SS - and potentially other T and NK cell-derived hematologic malignancies - PDX model generation. Furthermore, these studies advocate the thorough molecular understanding of the resultant PDX models to maximize their translational impact.
    MeSH term(s) Humans ; Animals ; Mice ; Skin Neoplasms/metabolism ; Interleukin-15 ; Lymphoma, T-Cell, Cutaneous/pathology ; Sezary Syndrome/metabolism ; Sezary Syndrome/pathology ; Lymphocytes/metabolism ; Tumor Microenvironment
    Chemical Substances Interleukin-15
    Language English
    Publishing date 2023-10-13
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2451104-3
    ISSN 1754-8411 ; 1754-8403
    ISSN (online) 1754-8411
    ISSN 1754-8403
    DOI 10.1242/dmm.050190
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: IL-4 and IL-13, not eosinophils, drive type 2 airway inflammation, remodeling and lung function decline.

    Scott, George / Asrat, Seblewongel / Allinne, Jeanne / Keat Lim, Wei / Nagashima, Kirsten / Birchard, Dylan / Srivatsan, Subhashini / Ajithdoss, Dharani K / Oyejide, Adelekan / Ben, Li-Hong / Walls, Johnathon / Le Floc'h, Audrey / Yancopoulos, George D / Murphy, Andrew J / Sleeman, Matthew A / Orengo, Jamie M

    Cytokine

    2022  Volume 162, Page(s) 156091

    Abstract: Rationale: Type 2 (T2) asthma is characterized by airflow limitations and elevated levels of blood and sputum eosinophils, fractional exhaled nitric oxide, IgE, and periostin. While eosinophils are associated with exacerbations, the contribution of ... ...

    Abstract Rationale: Type 2 (T2) asthma is characterized by airflow limitations and elevated levels of blood and sputum eosinophils, fractional exhaled nitric oxide, IgE, and periostin. While eosinophils are associated with exacerbations, the contribution of eosinophils to lung inflammation, remodeling and function remains largely hypothetical.
    Objectives: To determine the effect of T2 cytokines IL-4, IL-13 and IL-5 on eosinophil biology and compare the impact of depleting just eosinophils versus inhibiting all aspects of T2 inflammation on airway inflammation.
    Methods: Human eosinophils or endothelial cells stimulated with IL-4, IL-13 or IL-5 were assessed for gene changes or chemokine release.Mice exposed to house dust mite extract received anti-IL-4Rα (dupilumab), anti-IL-5 or control antibodies and were assessed for changes in lung histological and inflammatory endpoints.
    Measurements and main results: IL-4 or IL-13 stimulation of human eosinophils and endothelial cells induced gene expression changes related to granulocyte migration; whereas, IL-5 induced changes reflecting granulocyte differentiation.In a mouse model, blocking IL-4Rα improved lung function by impacting multiple effectors of inflammation and remodeling, except peripheral eosinophil counts, thereby disconnecting blood eosinophils from airway inflammation, remodeling and function. Blocking IL-5 globally reduced eosinophil counts but did not impact inflammatory or functional measures of lung pathology. Whole lung transcriptome analysis revealed that IL-5 or IL-4Rα blockade impacted eosinophil associated genes, whereas IL-4Rα blockade also impacted genes associated with multiple cells, cytokines and chemokines, mucus production, cell:cell adhesion and vascular permeability.
    Conclusions: Eosinophils are not the sole contributor to asthma pathophysiology or lung function decline and emphasizes the need to block additional mediators to modify lung inflammation and impact lung function.
    MeSH term(s) Animals ; Humans ; Mice ; Asthma/metabolism ; Chemokines/metabolism ; Cytokines/metabolism ; Endothelial Cells/metabolism ; Inflammation/metabolism ; Interleukin-13/metabolism ; Lung/metabolism ; Pneumonia/metabolism ; Interleukin-4/pharmacology
    Chemical Substances Chemokines ; Cytokines ; Interleukin-13 ; Interleukin-4 (207137-56-2)
    Language English
    Publishing date 2022-12-05
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1018055-2
    ISSN 1096-0023 ; 1043-4666
    ISSN (online) 1096-0023
    ISSN 1043-4666
    DOI 10.1016/j.cyto.2022.156091
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: The Activin/FLRG Pathway Associates with Poor COVID-19 Outcomes in Hospitalized Patients

    McAleavy, Megan / Zhang, Qian / Ehmann, Peter J. / Xu, Jianing / Wipperman, Matthew F. / Ajithdoss, Dharani / Pan, Li / Wakai, Matthew / Simonson, Raphael / Gadi, Abhilash / Oyejide, Adelekan / Hamon, Sara C. / Boyapati, Anita / Morton, Lori G. / Shavlakadze, Tea / Kyratsous, Christos A. / Glass, David J.

    Molecular and Cellular Biology. 2022 Jan. 1, v. 42, no. 1 p.e00467-21-

    2022  

    Abstract: A subset of hospitalized COVID-19 patients, particularly the aged and those with comorbidities, develop the most severe form of the disease, characterized by acute respiratory disease syndrome (ARDS), coincident with experiencing a “cytokine storm.” Here, ...

    Abstract A subset of hospitalized COVID-19 patients, particularly the aged and those with comorbidities, develop the most severe form of the disease, characterized by acute respiratory disease syndrome (ARDS), coincident with experiencing a “cytokine storm.” Here, we demonstrate that cytokines which activate the NF-κB pathway can induce activin A. Patients with elevated activin A, activin B, and FLRG at hospital admission were associated with the most severe outcomes of COVID-19, including the requirement for mechanical ventilation, and all-cause mortality. A prior study showed that activin A could decrease viral load, which indicated there might be a risk to giving COVID-19 patients an inhibitor of activin. To evaluate this, the role for activin A was examined in a hamster model of SARS-CoV-2 infection, via blockade of activin A signaling. The hamster model demonstrated that use of an anti-activin A antibody did not worsen the disease and there was no evidence for increase in lung viral load and pathology. The study indicates blockade of activin signaling may be beneficial in treating COVID-19 patients experiencing ARDS.
    Keywords COVID-19 infection ; Severe acute respiratory syndrome coronavirus 2 ; animal models ; antibodies ; cell biology ; cytokines ; hospitals ; lungs ; mortality ; respiratory tract diseases ; risk ; viral load ; activin A ; activin B ; FLRG ; FSTL3 ; SARS-Cov-2 ; COVID-19 ; acute respiratory disease syndrome ; ARDS
    Language English
    Dates of publication 2022-0101
    Publishing place Taylor & Francis
    Document type Article ; Online
    ZDB-ID 779397-2
    ISSN 1098-5549 ; 0270-7306
    ISSN (online) 1098-5549
    ISSN 0270-7306
    DOI 10.1128/MCB.00467-21
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  4. Article ; Online: The Activin/FLRG Pathway Associates with Poor COVID-19 Outcomes in Hospitalized Patients.

    McAleavy, Megan / Zhang, Qian / Ehmann, Peter J / Xu, Jianing / Wipperman, Matthew F / Ajithdoss, Dharani / Pan, Li / Wakai, Matthew / Simonson, Raphael / Gadi, Abhilash / Oyejide, Adelekan / Hamon, Sara C / Boyapati, Anita / Morton, Lori G / Shavlakadze, Tea / Kyratsous, Christos A / Glass, David J

    Molecular and cellular biology

    2021  Volume 42, Issue 1, Page(s) e0046721

    Abstract: A subset of hospitalized COVID-19 patients, particularly the aged and those with comorbidities, develop the most severe form of the disease, characterized by acute respiratory disease syndrome (ARDS), coincident with experiencing a "cytokine storm." Here, ...

    Abstract A subset of hospitalized COVID-19 patients, particularly the aged and those with comorbidities, develop the most severe form of the disease, characterized by acute respiratory disease syndrome (ARDS), coincident with experiencing a "cytokine storm." Here, we demonstrate that cytokines which activate the NF-κB pathway can induce activin A. Patients with elevated activin A, activin B, and FLRG at hospital admission were associated with the most severe outcomes of COVID-19, including the requirement for mechanical ventilation, and all-cause mortality. A prior study showed that activin A could decrease viral load, which indicated there might be a risk to giving COVID-19 patients an inhibitor of activin. To evaluate this, the role for activin A was examined in a hamster model of SARS-CoV-2 infection, via blockade of activin A signaling. The hamster model demonstrated that use of an anti-activin A antibody did not worsen the disease and there was no evidence for increase in lung viral load and pathology. The study indicates blockade of activin signaling may be beneficial in treating COVID-19 patients experiencing ARDS.
    MeSH term(s) Activins/blood ; Adult ; Aged ; Animals ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/therapeutic use ; COVID-19/drug therapy ; COVID-19/mortality ; COVID-19/virology ; Cell Line ; Cells, Cultured ; Cricetinae ; Double-Blind Method ; Female ; Follistatin-Related Proteins/blood ; Hospitalization/statistics & numerical data ; Humans ; Male ; Middle Aged ; Outcome Assessment, Health Care/methods ; Outcome Assessment, Health Care/statistics & numerical data ; SARS-CoV-2/drug effects ; SARS-CoV-2/physiology ; Severity of Illness Index ; Signal Transduction/drug effects ; Survival Rate
    Chemical Substances Antibodies, Monoclonal, Humanized ; Follistatin-Related Proteins ; activin A ; activin B ; Activins (104625-48-1) ; sarilumab (NU90V55F8I)
    Language English
    Publishing date 2021-11-01
    Publishing country United States
    Document type Clinical Trial, Phase II ; Clinical Trial, Phase III ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 779397-2
    ISSN 1098-5549 ; 0270-7306
    ISSN (online) 1098-5549
    ISSN 0270-7306
    DOI 10.1128/MCB.00467-21
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Blocking common γ chain cytokine signaling ameliorates T cell-mediated pathogenesis in disease models.

    Le Floc'h, Audrey / Nagashima, Kirsten / Birchard, Dylan / Scott, George / Ben, Li-Hong / Ajithdoss, Dharani / Gayvert, Kaitlyn / Romero Hernandez, Annabel / Herbin, Olivier / Tay, Amanda / Farrales, Pamela / Korgaonkar, Chandrashekhar K / Pan, Hao / Shah, Sweta / Kamat, Vishal / Chatterjee, Ishita / Popke, Jon / Oyejide, Adelekan / Lim, Wei Keat /
    Kim, Jee H / Huang, Tammy / Franklin, Matthew / Olson, William / Norton, Thomas / Perlee, Lorah / Yancopoulos, George D / Murphy, Andrew J / Sleeman, Matthew A / Orengo, Jamie M

    Science translational medicine

    2023  Volume 15, Issue 678, Page(s) eabo0205

    Abstract: The common γ chain (γc; IL-2RG) is a subunit of the interleukin (IL) receptors for the γc cytokines IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. The lack of appropriate neutralizing antibodies recognizing IL-2RG has made it difficult to thoroughly ... ...

    Abstract The common γ chain (γc; IL-2RG) is a subunit of the interleukin (IL) receptors for the γc cytokines IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. The lack of appropriate neutralizing antibodies recognizing IL-2RG has made it difficult to thoroughly interrogate the role of γc cytokines in inflammatory and autoimmune disease settings. Here, we generated a γc cytokine receptor antibody, REGN7257, to determine whether γc cytokines might be targeted for T cell-mediated disease prevention and treatment. Biochemical, structural, and in vitro analysis showed that REGN7257 binds with high affinity to IL-2RG and potently blocks signaling of all γc cytokines. In nonhuman primates, REGN7257 efficiently suppressed T cells without affecting granulocytes, platelets, or red blood cells. Using REGN7257, we showed that γc cytokines drive T cell-mediated disease in mouse models of graft-versus-host disease (GVHD) and multiple sclerosis by affecting multiple aspects of the pathogenic response. We found that our xenogeneic GVHD mouse model recapitulates hallmarks of acute and chronic GVHD, with T cell expansion/infiltration into tissues and liver fibrosis, as well as hallmarks of immune aplastic anemia, with bone marrow aplasia and peripheral cytopenia. Our findings indicate that γc cytokines contribute to GVHD and aplastic anemia pathology by promoting these characteristic features. By demonstrating that broad inhibition of γc cytokine signaling with REGN7257 protects from immune-mediated disorders, our data provide evidence of γc cytokines as key drivers of pathogenic T cell responses, offering a potential strategy for the management of T cell-mediated diseases.
    MeSH term(s) Animals ; Mice ; Anemia, Aplastic/metabolism ; Antibodies, Monoclonal/metabolism ; Cytokines/metabolism ; Graft vs Host Disease/metabolism ; Signal Transduction ; T-Lymphocytes/metabolism ; T-Lymphocytes/pathology ; Interleukin Receptor Common gamma Subunit/antagonists & inhibitors ; Interleukin Receptor Common gamma Subunit/metabolism ; Primates
    Chemical Substances Antibodies, Monoclonal ; Cytokines ; Interleukin Receptor Common gamma Subunit
    Language English
    Publishing date 2023-01-11
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2518854-9
    ISSN 1946-6242 ; 1946-6234
    ISSN (online) 1946-6242
    ISSN 1946-6234
    DOI 10.1126/scitranslmed.abo0205
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Enhanced IL-36R signaling promotes barrier impairment and inflammation in skin and intestine.

    Hovhannisyan, Zaruhi / Liu, Nengyin / Khalil-Aguero, Sara / Panea, Casandra / VanValkenburgh, Jeffrey / Zhang, Ruoyu / Lim, Wei Keat / Bai, Yu / Fury, Wen / Huang, Tammy / Garnova, Elena / Fairhurst, Jeanette / Kim, Jee / Aryal, Smita / Ajithdoss, Dharani / Oyejide, Adelekan / Del Pilar Molina-Portela, Maria / E, Hock / Poueymirou, William /
    Oristian, Nicole Stokes / Brydges, Susannah / Liu, Xia / Olson, William / Yancopoulos, George / Murphy, Andrew J / Sleeman, Matthew A / Haxhinasto, Sokol

    Science immunology

    2021  Volume 5, Issue 54

    Abstract: Deficiency in interleukin-36R (IL-36R) antagonist caused by loss-of-function mutations ... ...

    Abstract Deficiency in interleukin-36R (IL-36R) antagonist caused by loss-of-function mutations in
    MeSH term(s) Animals ; Biomarkers ; Dermatitis/etiology ; Dermatitis/metabolism ; Dermatitis/pathology ; Disease Models, Animal ; Disease Susceptibility ; Gastroenteritis/etiology ; Gastroenteritis/metabolism ; Gastroenteritis/pathology ; Humans ; Intestinal Mucosa/metabolism ; Intestinal Mucosa/pathology ; Mice ; Receptors, Interleukin-1/metabolism ; Signal Transduction ; Skin/metabolism ; Skin/pathology
    Chemical Substances Biomarkers ; Receptors, Interleukin-1
    Language English
    Publishing date 2021-01-13
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2470-9468
    ISSN (online) 2470-9468
    DOI 10.1126/sciimmunol.aax1686
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.

    Baum, Alina / Ajithdoss, Dharani / Copin, Richard / Zhou, Anbo / Lanza, Kathryn / Negron, Nicole / Ni, Min / Wei, Yi / Mohammadi, Kusha / Musser, Bret / Atwal, Gurinder S / Oyejide, Adelekan / Goez-Gazi, Yenny / Dutton, John / Clemmons, Elizabeth / Staples, Hilary M / Bartley, Carmen / Klaffke, Benjamin / Alfson, Kendra /
    Gazi, Michal / Gonzalez, Olga / Dick, Edward / Carrion, Ricardo / Pessaint, Laurent / Porto, Maciel / Cook, Anthony / Brown, Renita / Ali, Vaneesha / Greenhouse, Jack / Taylor, Tammy / Andersen, Hanne / Lewis, Mark G / Stahl, Neil / Murphy, Andrew J / Yancopoulos, George D / Kyratsous, Christos A

    Science (New York, N.Y.)

    2020  Volume 370, Issue 6520, Page(s) 1110–1115

    Abstract: An urgent global quest for effective therapies to prevent and treat coronavirus disease 2019 (COVID-19) is ongoing. We previously described REGN-COV2, a cocktail of two potent neutralizing antibodies (REGN10987 and REGN10933) that targets nonoverlapping ... ...

    Abstract An urgent global quest for effective therapies to prevent and treat coronavirus disease 2019 (COVID-19) is ongoing. We previously described REGN-COV2, a cocktail of two potent neutralizing antibodies (REGN10987 and REGN10933) that targets nonoverlapping epitopes on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. In this report, we evaluate the in vivo efficacy of this antibody cocktail in both rhesus macaques, which may model mild disease, and golden hamsters, which may model more severe disease. We demonstrate that REGN-COV-2 can greatly reduce virus load in the lower and upper airways and decrease virus-induced pathological sequelae when administered prophylactically or therapeutically in rhesus macaques. Similarly, administration in hamsters limits weight loss and decreases lung titers and evidence of pneumonia in the lungs. Our results provide evidence of the therapeutic potential of this antibody cocktail.
    MeSH term(s) Animals ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Neutralizing/therapeutic use ; COVID-19/prevention & control ; COVID-19/therapy ; Drug Combinations ; Macaca mulatta ; Mesocricetus
    Chemical Substances Antibodies, Monoclonal, Humanized ; Antibodies, Neutralizing ; Drug Combinations ; casirivimab and imdevimab drug combination
    Keywords covid19
    Language English
    Publishing date 2020-10-09
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 128410-1
    ISSN 1095-9203 ; 0036-8075
    ISSN (online) 1095-9203
    ISSN 0036-8075
    DOI 10.1126/science.abe2402
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.

    Smith, Eric J / Olson, Kara / Haber, Lauric J / Varghese, Bindu / Duramad, Paurene / Tustian, Andrew D / Oyejide, Adelekan / Kirshner, Jessica R / Canova, Lauren / Menon, Jayanthi / Principio, Jennifer / MacDonald, Douglas / Kantrowitz, Joel / Papadopoulos, Nicholas / Stahl, Neil / Yancopoulos, George D / Thurston, Gavin / Davis, Samuel

    Scientific reports

    2015  Volume 5, Page(s) 17943

    Abstract: Bispecific antibodies, while showing great therapeutic potential, pose formidable challenges with respect to their assembly, stability, immunogenicity, and pharmacodynamics. Here we describe a novel class of bispecific antibodies with native human ... ...

    Abstract Bispecific antibodies, while showing great therapeutic potential, pose formidable challenges with respect to their assembly, stability, immunogenicity, and pharmacodynamics. Here we describe a novel class of bispecific antibodies with native human immunoglobulin format. The design exploits differences in the affinities of the immunoglobulin isotypes for Protein A, allowing efficient large-scale purification. Using this format, we generated a bispecific antibody, REGN1979, targeting the B cell marker, CD20, and the CD3 component of the T cell receptor, which triggers redirected killing of B cells. In mice, this antibody prevented growth of B cell tumors and also caused regression of large established tumors. In cynomolgus monkeys, low doses of REGN1979 caused prolonged depletion of B cells in peripheral blood with a serum half-life of approximately 14 days. Further, the antibody induced a deeper depletion of B cells in lymphoid organs than rituximab. This format has broad applicability for development of clinical bispecific antibodies.
    MeSH term(s) Amino Acid Sequence ; Animals ; Antibodies, Bispecific/chemistry ; Antibodies, Bispecific/immunology ; Antibodies, Bispecific/isolation & purification ; Antibodies, Bispecific/pharmacology ; Antibody-Dependent Cell Cytotoxicity ; Antigens, CD20/immunology ; B-Lymphocytes/drug effects ; B-Lymphocytes/immunology ; B-Lymphocytes/metabolism ; CD3 Complex/immunology ; Cell Line, Tumor ; Chromatography, Affinity ; Cytokines/metabolism ; Cytotoxicity, Immunologic ; Disease Models, Animal ; Female ; Immunophenotyping ; Macaca fascicularis ; Mice ; Mice, Knockout ; Mice, SCID ; Models, Molecular ; Molecular Sequence Data ; Neoplasms/immunology ; Neoplasms/pathology ; Neoplasms/therapy ; Phenotype ; Protein Conformation ; Sequence Alignment ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism ; Tumor Burden/drug effects ; Tumor Burden/immunology
    Chemical Substances Antibodies, Bispecific ; Antigens, CD20 ; CD3 Complex ; Cytokines
    Language English
    Publishing date 2015-12-11
    Publishing country England
    Document type Journal Article
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/srep17943
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters

    Baum, Alina / Copin, Richard / Ajithdoss, Dharani / Zhou, Anbo / Lanza, Kathryn / Negron, Nicole / Ni, Min / Wei, Yi / Atwal, Gurinder S / Oyejide, Adelekan / Goez-Gazi, Yenny / Dutton, John / Clemmons, Elizabeth / Staples, Hilary M / Bartley, Carmen / Klaffke, Benjamin / Alfson, Kendra / Gazi, Michal / Gonzales, Olga /
    Dick, Edward / Carrion, Ricardo / Pessaint, Laurent / Porto, Maciel / Cook, Anthony / Brown, Renita / Ali, Vaneesha / Greenhouse, Jack / Taylor, Tammy / Andersen, Hanne / Lewis, Mark G / Stahl, Neil / Murphy, Andrew J / Yancopoulos, George D / Kyratsous, Christos A

    bioRxiv

    Abstract: An urgent global quest for effective therapies to prevent and treat COVID-19 disease is ongoing. We previously described REGN-COV2, a cocktail of two potent neutralizing antibodies (REGN10987+REGN10933) targeting non-overlapping epitopes on the SARS-CoV- ... ...

    Abstract An urgent global quest for effective therapies to prevent and treat COVID-19 disease is ongoing. We previously described REGN-COV2, a cocktail of two potent neutralizing antibodies (REGN10987+REGN10933) targeting non-overlapping epitopes on the SARS-CoV-2 spike protein. In this report, we evaluate the in vivo efficacy of this antibody cocktail in both rhesus macaques and golden hamsters and demonstrate that REGN-COV-2 can greatly reduce virus load in lower and upper airway and decrease virus induced pathological sequalae when administered prophylactically or therapeutically. Our results provide evidence of the therapeutic potential of this antibody cocktail.
    Keywords covid19
    Publisher BioRxiv; WHO
    Document type Article ; Online
    Note WHO #Covidence: #233320
    DOI 10.1101/2020.08.02.233320
    Database COVID19

    Kategorien

  10. Article ; Online: REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters

    Baum, Alina / Copin, Richard / Ajithdoss, Dharani / Zhou, Anbo / Lanza, Kathryn / Negron, Nicole / Ni, Min / Wei, Yi / Atwal, Gurinder S / Oyejide, Adelekan / Goez-Gazi, Yenny / Dutton, John / Clemmons, Elizabeth / Staples, Hilary M / Bartley, Carmen / Klaffke, Benjamin / Alfson, Kendra / Gazi, Michal / Gonzales, Olga /
    Dick, Edward / Carrion, Ricardo / Pessaint, Laurent / Porto, Maciel / Cook, Anthony / Brown, Renita / Ali, Vaneesha / Greenhouse, Jack / Taylor, Tammy / Andersen, Hanne / Lewis, Mark G / Stahl, Neil / Murphy, Andrew J / Yancopoulos, George D / Kyratsous, Christos A

    bioRxiv

    Abstract: An urgent global quest for effective therapies to prevent and treat COVID-19 disease is ongoing. We previously described REGN-COV2, a cocktail of two potent neutralizing antibodies (REGN10987+REGN10933) targeting non-overlapping epitopes on the SARS-CoV- ... ...

    Abstract An urgent global quest for effective therapies to prevent and treat COVID-19 disease is ongoing. We previously described REGN-COV2, a cocktail of two potent neutralizing antibodies (REGN10987+REGN10933) targeting non-overlapping epitopes on the SARS-CoV-2 spike protein. In this report, we evaluate the in vivo efficacy of this antibody cocktail in both rhesus macaques and golden hamsters and demonstrate that REGN-COV-2 can greatly reduce virus load in lower and upper airway and decrease virus induced pathological sequalae when administered prophylactically or therapeutically. Our results provide evidence of the therapeutic potential of this antibody cocktail.
    Keywords covid19
    Language English
    Publishing date 2020-08-03
    Publisher Cold Spring Harbor Laboratory
    Document type Article ; Online
    DOI 10.1101/2020.08.02.233320
    Database COVID19

    Kategorien

To top